Eid RA, Zaki MSA, Alaa Eldeen M, Alshehri MM, Shati AA, El-Kott AF
Some scientific publications also consider DSIP as a co-regulator of other neurohormonal systems, including somatotropin, prolactin, and ACTH, especially in the context of adaptation to physical exertion, overtraining, and chronic stress
Supplemental ALCAR is thought to play an important role in protecting and supporting brain and muscle function
*Significance level 5%
Sources Novo Nordisk NDA filing for CagriSema, December 18, 2025 American Diabetes Association REDEFINE-1 and REDEFINE-2 results, ADA 2026 Scientific Sessions HCPLive REDEFINE-1 Phase 3 safety and efficacy data Clinical Trials Arena REDEFINE-4: CagriSema vs tirzepatide head-to-head, February 2026 Life Science Daily News CagriSema FDA review timeline and NDA update, July 2026 PharmExec REDEFINE-1 results: CagriSema falls short of 25% weight loss target Drugs.com CagriSema FDA approval status history New England Journal of Medicine REDEFINE-1 full publication (presented at ADA 2026) Novo Nordisk REIMAGINE Phase 3 diabetes trial results, ADA 2026 and The Lancet FDA Wegovy (semaglutide) prescribing information, 2025 Related reading on Heally: What is Wegovy HD
